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Glucokinase Hyperinsulinism (GCK-HI) is a rare variant of congenital 
hyperinsulinism caused by activating mutations in the glucokinase gene 
resulting in overactivity of glucokinase within the pancreatic -cell. Until now 
seven families with this condition have been described. Here we report on a 
new patient presenting already with increased birthweight and neonatal 
hypoglycemia. The patient was initially diagnosed to suffer from transient 
hyperinsulinism and was reevaluated at the age of 3 years with developmental 
delay. Morning glucose after an overnight fast was 2.5-3.6 mmol/l. Fasting tests 
revealed supressed insulin secretion at the end of fasting (1.4-14.5 pmol/l). 
Mutational analysis showed a novel heterozygous missense mutation in exon 
10 c.1354G>C (p.Val452Leu). Functional characteristics of GK-V452L clearly 
illustrated overactivity of this mutation after expression in Escherichia coli as a 
glutathionyl S-transferase (GST) fusion protein. On the basis of diagnostic 
difficulties in this patient we reviewed the literature for diagnostic criteria for 
GCK-HI. There was no single consistent diagnostic criterion found. Insulin 
concentration at hypoglycemia, fasting test as well as reactive hypoglycemia 
after an oral glucose tolerance test were not conclusive for all patients. 
Particularly adults with milder symptoms of hypoglycemia as episodes of 
extreme hunger or sweatiness were only identified genetically within the family 
screening. 
Therefore GCK-HI as an autosomal dominat inherited condition might be 
underestimated. Mutational analysis of the GCK-gene should be performed in 
all individuals with unclear episodes of hypoglycemia even without documented 
hyperinsulinism during hypoglycemia after fasting.  Delay of diagnosis might 
results in mental handicaps of the affected individuals. 
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Congenital Hyperinsulinism (HI) is a heterogenic group of genetic 
disorders of the pancreatic -cells characterized by recurrent episodes of 
hypoglycemia due to an inappropriate secretion of insulin (1-2). Abnormalities in 
several different genes have been found to be responsible for about 55% of the 
cases of HI (3). However, the molecular etiology of the remaining 45% remains 
unknown.  
Mutations in the  cell sulfonylurea receptor (SUR1, ABCC8) are the 
most common cause of HI, responsible for 45% of cases (4). Other genes 
involved include the inward cell rectifying potassium channel (Kir6.2, KCNJ11) 
(5), Glutamate dehydrogenase (GLUD1) (6), short chain 3-hydroxy-acyl-CoA 
dehydrogenase (SCHAD, HADHSC) (7) and Glucokinase (GCK) (8). The latter 
appears to be a very rare cause of HI, with only seven cases described to date 
in the world literature (8-12). HI is an extremely heterogeneous disorder in all 
aspects, including clinical presentation, morphology and genetics. Since the 
hypoglycemia associated with the disease can cause permanent neurological 
damage (13), both prompt diagnosis and early treatment are essential. 
The glycolytic enzyme Glucokinase (GK) functions as the “glucose 
sensor” in the pancreatic -cells and as such regulates glucose stimulated 
insulin secretion (GSIS) (14). The structural integrity of GK is crucial for the 
maintenance of normal glucose homeostasis. Activating mutations in 
glucokinase gene (GCK) result in HI (GCK-HI), both mild and severe forms (8-
12,14).  
Here we describe a new patient with GCK-HI due to a de novo mutation 
in GCK. We also demonstrate diagnostic difficulties of this disorder for this 
patient and the so far published individuals. GCK-HI might be misdiagnosed as 
“unclear” or “idiopathic” hypoglycemia, or as transient hyperinsulinemic 
hypoglycemia, due to these diagnostic problems. 
  
Case Report 
The child was the first offspring of healthy non-consanguineous German 
parents. Family history was negative for hyperinsulinism or diabetes. There was 
marked macrosomia of the newborn with a birth weight of 5860g and a length of 
60cm. Recurrent low blood glucose levels were measured in the first day of life. 
At the third day of life the male newborn was admitted to the ICU of the local 
children hospital due to hypoglycemia and was treated with i.v. glucose. 
Hyperinsulinism was suspected. At 14 days of life the i.v. glucose was stopped 
and changed completely to oral carbohydrates in addition to frequent 
feeding. The patient was finally discharged with diagnosis of "transient 
hyperinsulinism" without special diet or medication and with glucose 
concentrations of 2.6-3.3 mmol/l. At the age of 3 years he was sent to the 
neurology outpatient clinic of our hospital for evaluation of speech delay and 
mental retardation. The patient’s mental state was evaluated with Snijders-
Oomen Non-verbal Intelligence test (SON-R 2 ½ -7) and revealed an IQ of 86 
with marked problems in his concentration ability.  Glucose monitoring on the 
ward revealed persistence of low glucose concentrations (1.7-4.3 mmol/l) with 
low glucose levels particularly after the night fast (Figure 1). The patient was 
evaluated by fasting test and oral glucose tolerance test (OGTT) (Figure 2, 
Figure 3). Hyperinsulinism was suspected because of the neonatal history and 
mutational analysis was performed for the so far described genes for HI 
(ABCC8, KCNJ11, GCK, GLUD1). The patient was discharged with dietary 
recommendations. After diagnosing GCK-HI a treatment with diazoxide was 
started (6-8 mg/kg/d). Diazoxide was not futher increased because next to the 
hypertrichosis as side effect parents reported a loss of appetite. A repeat of the 
SON-R 2,5-7 intelligence test at 4 years and 3 month revealed now an IQ of 
105. Today at 4 years and 9 month of age the patient is able to bicycle and to 
swim. Despite diazoxide (7mg/kg/day) his fasting glucose often drops again to 
2.0-2.5 mmol/l and diazoxide was increased again. However, the opinion of 
parents and medical staff is that the patient markedly improved after the start of 
diazoxide treatment.  
 
Laboratory methods 
Sequencing of the glucokinase gene  
 After extracting genomic DNA from peripheral lymphocytes of the 
proband all coding exons and exon/intron boundaries of the ABCC8-, KCNJ11-, 
GCK- and GLUD1-gene were amplified by PCR, purified and sequenced at the 
IntegraGen laboratory Bonn using the Big_Dye Terminator v3.1 cycle 
sequencing kit and the ABI PRISM DNA Analyzer 3730. Subsequently DNA 
samples of the patients parents were checked for the presence of the identified 
GCK mutation. In order to confirm the identified mutation all coding exons and 
exon/intron boundaries of GCK gene were amplified by PCR, purified and 
sequenced at Integragen laboratories using the Big Dye Terminator kit (Perkin-
Elmer Wellesley, MA, USA) and the ABI PRISM DNA Analyzer 3700 (Perkin-
Elmer Wellesley, MA, USA). The variant detected in exon 10 of GCK was 
identified by direct sequencing and verified by digestion with the restriction 
endonuclease BbvI.  
 
.  
Glucose and insulin measurements:  
A standard (1.75g/ kg) OGTT was performed after 12 h of overnight 
fasting. Blood samples for the determination of plasma glucose and serum 
insulin were drawn at 0, 30, 60, 120 and 160 min. Plasma glucose during the 
OGTT was measured with a hexokinase method using a Roche/Hitachi® 
device. The glucose monitoring on the ward was also performed with a glucose 
oxidase method using a ecoSolo II® by care diagnostica® Germany. Serum 
insulin at the OGTT and the fasting test was measured with the 
electrochemiluminescence immunoassay “ELICA” on a cobas® e immunoassay 
analyzer by Roche Diagnostics® Mannheim, Germany.  
 
 
Site-directed mutagenesis and functional analysis of the GK protein 
 
The methods have been described before in detail (15). The V452L 
mutation of the GCK gene was introduced into the wild type human pancreatic 
GCK using the Quick Change site-directed mutagenesis kit from Stratagene (La 
Jolla, CA).  Plasmid pUC-GkB was used as a template in PCR reactions. The 
mutant was sequenced to confirm that only the desired mutation was 
introduced. The mutated plasmid (pUC-GkBV452L) was digested with EcoRI 
and SalI.  Subsequently, the insert was sub-cloned into plasmid pGEX-6P-1 
(Amersham Pharmacia) to allow its expression in Escherichia coli as a 
glutathionyl S-transferase (GST) fusion protein and its purification by affinity 
chromatography using GSH-sepharose beads. The purified recombinant GST-
GK protein was routinely screened for purity by SDS-PAGE. Studies of the 
kinetic properties of the wild type protein (GK-WT) and GK-V452L were 
performed spectrophotometrically as described previously (15). The kinetic 
assays were performed in a tuneable VERSAmax microplate reader. We used 
non-linear kinetics according to the Hill equation to determine the affinity of the 
enzyme for glucose. In order to measure the glucose phosphorylation capacity 
of the enzyme we used the relative activity index, which was calculated 




The direct sequencing of GCK of the proband revealed a novel 
heterozygous missense mutation in exon 10 c.1354G>C, p.Val452Leu (V452L). 
This variant was not found in any other family members or in 100 healthy 
control chromosomes. Since the mutation was not found in the parents and the 
paternity test revealed parenthood of the parents tested the mutation V452L 
was considered as “de novo”.  
 
The results of functional studies of GK-WT and GK-V452L are presented 
in Table 1. The S0.5 of GK-V452L obtained was two fold lower than that for GK-
WT. The Hill coefficient decreased moderately, indicating lower cooperativity of 
the enzyme. The turnover rate of GK-V452L tended to be lower than that of GK-
WT, however the efficacy (Kcat/S0.5) of the GK-V452L was almost two fold 
higher. The affinity of GK-V452L for its second substrate, MgATP2-, was the 
same as that for GK-WT. The relative activity index, as an expression of -cell 
glucose usage of the enzyme, was markedly increased for GK-V452L (Table 1). 
These kinetic characteristics suggest that GK-V452L was the cause of the 
hyperinsulinism in the patient.  
In order to study the impact of GK-V452L on the threshold for GSIS, and 
therefore on glucose homeostasis we used a previously described 
mathematical model that takes into account the impact of blood glucose levels 
on the expression of GK for both alleles (15). The threshold for GSIS predicted 
by this model for GK-V452L was 1.9 mmol/l in contrast to the physiological 
threshold of 5 mmol/l (Table 1, Figure 4). This model illustrates the physiological 
consequences of the GK-V452L protein on GSIS and therefore on glucose 
homeostasis.  When compared to a similar analysis of other disease-causing 
GCK mutations, this novel mutation is ranked similar to A456V and G68V (Fig. 
3).   
 
The oral glucose tolerance test (OGTT) presented glucose values of 1.8 mmol/l 
at 160 min with, interestingly, also low insulin values (Figure 3). Glucose 
monitoring in our patient showed recurrent low glucose concentrations (1.7-4.3 
mmol/l) particularly after the night fast (Figure 1). The fasting test revealed 
different suppressed insulin concentrations (1.4-14.5 pmol/l) at 14, 16 and 18 
hours of fasting without severe hypoglycemia (lowest glucose concentration at 
18 h was 2.2 mmol/l), and again with low insulin values of 1.4 pmol/l (Figure 2). 
 
Discussion 
The critical role played by GK in the maintenance of glucose 
homeostasis is demonstrated by the fact that mutations in GCK will lead to a 
monogenic metabolic disease of the pancreatic β-cell. Indeed, heterozygous 
and homozygous inactivating mutations result in a type of monogenic diabetes 
known as maturity onset diabetes of the young 2 (MODY2) (16), and permanent 
neonatal diabetes (17) respectively, while activating mutations result in HI 
(GCK-HI) (8). There are only seven activating GCK mutations described and 
found in six families and one individual (8-12,18) (Table 2). The clinical 
phenotype of this type of monogenic hyperinsulinism turned out to be highly 
heterogeneous, resulting in both mild and severe forms (8-12,18). 
 
Our proband is the second patient diagnosed with GCK-HI who presents 
a “de novo” GCK activating mutation and also has mental retardation. However, 
in two other unrelated patients with GCK-HI previously described, the GCK 
activating mutation was also considered “de novo” in one of their parents. 
Therefore, if we consider four “de novo” GCK activating mutations out of eight 
described so far, the probability of “de novo” activating mutation in GCK is 
importantly high (50%).  
 
Although the prevalence of GCK-HI today is very low, the high frequency 
of “de novo” activating mutations in this gene and the heterogeneity in both age 
of onset and clinical presentation, lead to potential diagnostic difficulties of 
GCK-HI. The diagnostic criteria for HI are mainly the increased carbohydrate 
intake needed to prevent hypoglycemia and elevated insulin concentrations 
during hypoglycemia that demonstrate a lack of the physiological suppression of 
insulin secretion at low glucose concentrations. In transitory hyeprinsulinism, 
the blood glucose levels are usually stabilized after treatment with carbohydrate 
intake and intravenous glucose infusion, and patients are discharged with 
dietary recommendations. Our patient was treated with intravenous glucose 
only for the first two weeks of life, and then was discharged, hence the 
diagnosis of “transient hyperinsulinism”. The clinical manifestation of GCK-HI in 
the neonatal periode is heterogeneous. Indeed, of five patients with GCK-HI 
diagnosed in the neonatal period, including our proband, only in two cases the 
hyperinsulinism was permanent (9,11). In the three other cases of GCK-HI, one 
patient was asymptomatic (10) and two treated with intravenous glucose 
infusion and discharge on standard formula milk (10) and with no medication, 
like in our proband. These three last cases, therefore, were susceptible of being 
diagnosed as “transient hyperinsulinism”. In all these patients with GCK-HI 
diagnosed as transitory neonatal hyperinsulinism, the blood glucose levels will 
be always low with the risk of neurological damage later in life. In infants 
feeding at four weeks of age is usually done every four hours, whereas the 
fasting episode will be prolonged during the first year of life up to eleven hours. 
This might cause a worsening of fasting hypoglycemia.  In fact, the patient who 
was asymptomatic presented at the age of 15 years with seizures. The second 
patient presented a more severe hyperinsulinemic hypoglycemia at infancy, and 
our patient presented the hyperinsulinemic hypoglycemia in the childhood with 
speech delay and mental retardation.  
 
The consideration of this heterogeneity in the clinical manifestation of 
GCK-HI in the neonatal period is highly important since any transitory neonatal 
hyperinsulinism can be in fact a case of transitory GCK-HI that will appears 
again later in life and, with very high probability, with neurological damage due 
to the long hypoglycemia period (13). None of these patients were genetically 
tested at the moment of the first diagnosis of hyperinsulinemic hypoglycemia, 
consequently, both prompt genetic analysis and diagnosis as well as early 
treatment are critical to avoid the neurological damage. Furthermore in patients 
with seizures of unknown origin or in individuals with episodes of extreme 
hunger and symptoms of hypoglycemia, learning problems or development 
delay, fasting hypoglycemia should be ruled out. This is not only important in 
childhood since many of the GCK-HI individuals reported today were diagnosed 
as adults by family screening (Table 2). In some relatives (8,9,10,12) of affected 
individuals, a screening for GCK-mutation was performed and almost all of the 
GCK-mutation positive identified family members had a positive medical history 
for hypoglycaemic symptoms. Only two of them had never hypoglycaemic 
symptoms in history (Table 2; B1 and D1) but they had a pathological fasting 
test (Table 3, Figure 5) and a pathological OGTT (Figure 6, see individual D1) 
 
 In patients with HI diagnosed after the neonatal period, the insulin 
concentrations during fasting test or at spontaneous hypoglycemia are usually 
elevated. However, the evaluation of insulin concentration in GCK-HI patients 
revealed that the insulin values are not always elevated at hypoglycemia  (Table 
3, Figure 5). In fact, in our patient the insulin concentration dropped to a value 
of 1.4 pmol/l with a glycemia of 2.2 mmol/l. Likewise, OGTT in our patient 
showed low insulin secretion at 120 and 160 minutes (Figure 3). The low insulin 
secretion found in many GCK-HI patients at the time of hypoglycemia is 
probably due to the effect of the GCK-mutation on the glucose liver metabolism.  
Since hepatic and pancreatic glucokinase are encoded by a single gene with 
two distinct cell-specific promoters hepatic mutated GK will be activated in 
GCK-HI. 99% of the GK enzyme has been proposed to reside in the hepato-
parenchymal cells. There it serves a critical role in postprandial glucose clearing 
from circulation [19]. Overactivity of liver GK will result in enhanced glycolysis 
despite low glucose concentrations.  At a point of time, when insulin levels are 
already low in a fasting situation or postprandial state this might further trigger 
hypoglycemia.  
Pharmacological treatment of GCK-HI patients is also difficult to 
establish. Indeed, although early studies suggested that GCK-HI is a mild form 
of HI with good respond to diazoxide in low or medium dosage (8,9), in a more 
severe case of GCK-HI, treatment with high dosage of diazoxide (20mg/kg/day) 
in combination with chlorothiazide and nifidepin did not result in euglycemia 
(10).  In a patient recently reported (12), the response to low dosage of 
diazoxide was limited and additional octreotide was used. Though our patient 
showed an initial response to diazoxide in a medium dosage (8.0 mg/kg/day), 
he had again recurrent episodes of hypoglycemia after the night fast with nearly 
the same dosage (6.8 mg/kg/d) later. Data about octreotide treatment in GCK-
HI are very limited. In one patient octreotide was stopped because of the 
frequent injections needed without using continuous subcutaneous pumping 
system (10). The insufficient response of patients to drugs inhibiting insulin 
secretion might be due to the -cell-independent effect of glucokinase 
overactivity in the liver and corresponding increased hepatic glucose clearence. 
 
 In summary, most individuals with GCK-HI did not need any treatment 
despite dietary intervention when they present a mild phenotype. There might 
be a good response to diazoxide at low to medium dosage in the more severe 
affected individuals, but there are also some patients that do not completely 
respond to diazoxide at least in medium concentrations. Higher doses of 
diazoxide are sometimes not accepted by the parents of patients because of 
severe hypertrichosis, but there might be also other factors as the loss of 
appetite reported in our patient. Furthermore the same dosage may be less 
effective over the time (9). 
 
The outcome of the patients that are known today is also highly variable. 
Some individuals never had any symptoms of hypoglycemia and without 
pathological neurology despite recurrent fasting hypoglycemia (8,9). From the 
24 patients reported so far one patient was severely handicapped with mental 
retardation and epilepsy (11) and three had minor problems as learning 
difficulties or learning handicap (12). Our patient clearly improved clinically from 
diazoxide treatment. His concentrativeness was much better and whereas he 
was initially tested as mentally retarded at follow up he did caught up and was 
completely normal tested. 
 
In conclusion, GCK-HI is a rarely identified condition. This might be due 
to the often mild symptoms, the difficulties in diagnosing this disorder and the 
limited awareness for GCK-HI. The high frequency of spontaneous mutation in 
patients with GCK-HI along with the high risk of developing mental retardation, 
hypoglycemic seizures, or recurrent symptoms of hypoglycemia means that any 
newborn with hypoglycemia of unknown origin not resolving in the first weeks of 
life, or with transient hyperinsulinism, should be tested for GCK mutations. 
Furthermore mutational analysis of the GCK gene has to be included also in 
older children, as well as in adults if fasting hypoglycemia of unknown origin has 
been found. Identification of up to now not diagnosed patients will help to treat 
these patients properly by diet or medication.  
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